Candida vulvovaginitis natural history, complications and prognosis
Candida vulvovaginitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Candida vulvovaginitis natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Candida vulvovaginitis natural history, complications and prognosis |
FDA on Candida vulvovaginitis natural history, complications and prognosis |
CDC on Candida vulvovaginitis natural history, complications and prognosis |
Candida vulvovaginitis natural history, complications and prognosis in the news |
Blogs on Candida vulvovaginitis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2], Aravind Kuchkuntla, M.B.B.S[3]
Overview
Candida vulvovaginitis is a self limiting disease with no complications. Candida vulvovaginitis is very responsive to local or oral antifungals.
Natural History, Complications and Prognosis
Natural History
Candida vulvovaginitis is a common infection of women in reproductive age group. Patients present with vulvar pruritus, dysuria, and vaginal discharge. Half of the affected patients have multiple episodes of the infection and less than 10% have recurrent infection.[1]
Prognosis
Candida albicans vulvovaginitis has excellent prognosis with azole therapy. Patients with non-Candida albicans infections are prone to have recurrence and treatment with boric acid and oral fluconazole has good prognosis.[2]
Complications
Candida vulvovaginitis is a self limiting disease with no complications.
References
- ↑ Fidel PL, Vazquez JA, Sobel JD (1999). "Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans". Clin Microbiol Rev. 12 (1): 80–96. PMC 88907. PMID 9880475.
- ↑ Fidel PL, Vazquez JA, Sobel JD (1999). "Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans". Clin Microbiol Rev. 12 (1): 80–96. PMC 88907. PMID 9880475.